Charles Schwab Investment Management Inc. Invests $2.23 Million in Upstream Bio, Inc. (NASDAQ:UPB)

Charles Schwab Investment Management Inc. bought a new stake in Upstream Bio, Inc. (NASDAQ:UPB) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 135,323 shares of the company’s stock, valued at approximately $2,225,000. Charles Schwab Investment Management Inc. owned approximately 0.25% of Upstream Bio as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also made changes to their positions in UPB. Moody Aldrich Partners LLC acquired a new position in Upstream Bio during the 4th quarter valued at about $1,229,000. Rhumbline Advisers purchased a new stake in Upstream Bio during the fourth quarter valued at about $275,000. Bank of New York Mellon Corp purchased a new position in shares of Upstream Bio during the fourth quarter valued at $607,000. Finally, US Bancorp DE acquired a new stake in shares of Upstream Bio during the 4th quarter valued at $27,000.

Upstream Bio Trading Up 0.9 %

Shares of UPB opened at $6.87 on Friday. The business’s fifty day simple moving average is $8.63. Upstream Bio, Inc. has a 12 month low of $6.63 and a 12 month high of $29.46.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.